Hardman Johnston Global Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Hardman Johnston Global Advisors LLC

$2.46 Billion
Q3 2024

A detailed history of Hardman Johnston Global Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hardman Johnston Global Advisors LLC holds 114,909 shares of VRTX stock, worth $45.6 Million. This represents 2.17% of its overall portfolio holdings.

Number of Shares

114,909

Previous 121,820 5.67%

Holding current value

$45.6 Million

Previous $57.1 Million 6.41%

% of portfolio

2.17%

Previous 2.29%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	SELL	$460.0 - $505.78 $3.18 Million - $3.5 Million	-6,911 Reduced 5.67%	114,909 $53.4 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $14.5 Million - $17.9 Million	-36,961 Reduced 23.28%	121,820 $57.1 Million
Q1 2024 May 06, 2024	SELL	$407.69 - $446.08 $5.78 Million - $6.33 Million	-14,180 Reduced 8.2%	158,781 $66.4 Million
Q4 2023 Jan 29, 2024	SELL	$343.0 - $410.68 $988,526 - $1.18 Million	-2,882 Reduced 1.64%	172,961 $70.4 Million
Q3 2023 Oct 20, 2023	SELL	$338.18 - $362.46 $546,837 - $586,097	-1,617 Reduced 0.91%	175,843 $61.1 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $3.1 Million - $3.47 Million	-9,864 Reduced 5.27%	177,460 $62.4 Million
Q1 2023 May 05, 2023	SELL	$283.23 - $323.1 $5.5 Million - $6.27 Million	-19,403 Reduced 9.39%	187,324 $59 Million
Q4 2022 Feb 03, 2023	SELL	$285.76 - $321.48 $2.08 Million - $2.34 Million	-7,273 Reduced 3.4%	206,727 $59.7 Million
Q3 2022 Nov 02, 2022	SELL	$273.83 - $305.53 $4.91 Million - $5.47 Million	-17,914 Reduced 7.72%	214,000 $62 Million
Q2 2022 Aug 02, 2022	SELL	$234.96 - $292.55 $3.08 Million - $3.83 Million	-13,090 Reduced 5.34%	231,914 $65.4 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $8.06 Million - $9.49 Million	36,380 Added 17.44%	245,004 $63.9 Million
Q4 2021 Jan 26, 2022	BUY	$177.01 - $223.45 $3.53 Million - $4.46 Million	19,950 Added 10.57%	208,624 $45.8 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $635,771 - $711,479	-3,505 Reduced 1.82%	188,674 $34.2 Million
Q2 2021 Aug 09, 2021	SELL	$187.49 - $221.1 $752,772 - $887,716	-4,015 Reduced 2.05%	192,179 $38.7 Million
Q1 2021 May 12, 2021	BUY	$207.02 - $241.31 $103,510 - $120,655	500 Added 0.26%	196,194 $42.2 Million
Q4 2020 Feb 11, 2021	SELL	$207.01 - $276.09 $203,904 - $271,948	-985 Reduced 0.5%	195,694 $46.3 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $642,959 - $762,296	-2,515 Reduced 1.26%	196,679 $53.5 Million
Q2 2020 Jul 23, 2020	SELL	$225.48 - $295.8 $4.28 Million - $5.61 Million	-18,960 Reduced 8.69%	199,194 $57.8 Million
Q1 2020 May 04, 2020	SELL	$199.77 - $247.81 $209,758 - $260,200	-1,050 Reduced 0.48%	218,154 $51.9 Million
Q4 2019 Feb 05, 2020	SELL	$166.71 - $223.91 $1.34 Million - $1.8 Million	-8,056 Reduced 3.54%	219,204 $48 Million
Q3 2019 Oct 30, 2019	SELL	$166.23 - $187.09 $297,551 - $334,891	-1,790 Reduced 0.78%	227,260 $38.5 Million
Q2 2019 Aug 05, 2019	SELL	$164.61 - $190.37 $1.57 Million - $1.81 Million	-9,520 Reduced 3.99%	229,050 $42 Million
Q1 2019 May 03, 2019	SELL	$163.73 - $194.7 $657,375 - $781,720	-4,015 Reduced 1.66%	238,570 $43.9 Million
Q4 2018 Feb 06, 2019	SELL	$151.91 - $192.21 $1.46 Million - $1.85 Million	-9,635 Reduced 3.82%	242,585 $40.2 Million
Q3 2018 Oct 18, 2018	SELL	$167.73 - $192.74 $659,178 - $757,468	-3,930 Reduced 1.53%	252,220 $48.6 Million
Q2 2018 Jul 18, 2018	BUY	$145.72 - $169.96 $9.8 Million - $11.4 Million	67,250 Added 35.6%	256,150 $43.5 Million
Q1 2018 Apr 30, 2018	BUY	$151.6 - $177.13 $28.6 Million - $33.5 Million	188,900 New	188,900 $30.8 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hardman Johnston Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hardman Johnston Global Advisors LLC with notifications on news.

Account

Hardman Johnston Global Advisors LLC Vertex Pharmaceuticals Inc Transaction History